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In this review, we advance a new concept in developing vaccines and/or drugs to
target speciﬁc proteins expressed during the early stage of Bacillus anthracis (an-
thrax) infection and address existing challenges to this concept. Three proteins
(immune inhibitor A, GPR-like spore protease, and alanine racemase) initially
identiﬁed by proteomics in our laboratory were found to have diﬀerential expres-
sions during anthrax spore germination and early outgrowth. Other studies of
diﬀerent bacillus strains indicate that these three proteins are involved in either
germination or cytotoxicity of spores, suggesting that they may serve as potential
targets for the design of anti-anthrax vaccines and drugs.
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Introduction
Bacillus anthracis (anthrax) spores were distributed
through the postal system as biological weapons in
the US in the autumn of 2001, resulting in cases of
cutaneous and inhalational anthrax. It has been re-
ported that the mortality associated with inhalational
anthrax was 45% (1 ). There are three clinical forms
of anthrax: cutaneous, inhalational and gastrointesti-
nal (2 ). Ciproﬂoxacin has become a treatment of
choice for all clinical forms of anthrax owing to po-
tential resistance to penicillins and tetracyclines, and
demonstrated eﬃcacy in a primate model (1 ). An-
thrax possesses a penicillinase gene and a constitutive
cephalosporinase. Additionally, it is reported that the
former Soviet Union engineered penicillin and tetra-
cycline resistant anthrax spores (3 ). The infection
cycle of Bacillus anthracis (anthrax) is progressive.
The initial stage of infection occurs when pathogenic
spores interact with macrophages at the site of host
entry (4 ). Once inhaled, spores germinate while asso-
ciated with alveolar macrophages traveling en route
to regional lymph nodes. During systemic anthrax in-
fection, late stage events include vegetative growth in
the blood to very high titers and synthesis of the anth-
rax toxins, causing disease symptoms and ultimately
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death (5 , 6 ). Contemporary anthrax therapy focuses
on three-component toxins: protective antigen (PA),
lethal factor (LF), and edema factor (EF), which are
produced by vegetative cells during the late stage of
anthrax infection (7 ). Targeting PA has been vari-
ably eﬀective, and the ability of existing PA-targeting
methods to protect humans against inhalational an-
thrax that might be released by biological weapons
is an open question. Targeting the early stages of
anthrax infection (macrophage interaction, germina-
tion, and early outgrowth) may be more eﬀective
than targeting PA, LF, and/or EF in counteracting
anthrax in that the upstream events that lead to
their production could be prevented. Several factors
favor developing interventions that target the early
stages of anthrax infection. First, the interaction be-
tween spores and macrophages is an upstream event
in the life cycle of anthrax. The interruption of up-
stream events (macrophage interaction, germination
and early outgrowth) precludes downstream events
including the production of PA, LF, or EF. Second,
PA, LF, and EF are encoded by a plasmid in an-
thrax. Therefore, by replacing this plasmid with oth-
ers that encode virulent toxins (e.g., tetanus toxin,
cobra toxin, etc.), bioterrorists could potentially in-
troduce mutant anthrax spores that produce toxins
other than PA/LF/EF. Third, vegetative cells may
develop antibiotic resistance over time or, bioterror-
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ists might incorporate antibiotic-resistance genes into
such cells. Lastly, in contrast to toxins and antibiotic
resistance that are prone to change, macrophage inter-
action and germination factors are highly conserved
and less likely to be altered (8 ). Thus, blocking up-
stream events with vaccines and/or inhibitory drugs
may prevent the use of anthrax spores as bioweapons.
The objective of this article is to draw your attention
that while the vast majority of anti-anthrax works
center around PA/LF/EF, proteins expressed during
the early anthrax infection are potential targets for
the development of anti-anthrax vaccines or drugs.
Bacillus anthracis (anthrax)
Bacillus anthracis, the causative agent of anthrax,
is an endospore-forming, gram-positive, aerobic, and
rod-shaped bacterium (9 ). The dormant spores of an-
thrax are formed during sporulation, a process trig-
gered by starvation or harsh environment. They have
high resistance to heat, radiation, desiccation, pH ex-
tremes and toxic chemicals (10 ). As shown in Figure
1, the dormant spores have a unique and complicated
structural anatomy. The mature spore is made up
of diﬀerent zones, an exosporium on the outside with
multi-layered spore coats below, a cortex, and a cen-
tral core. Between the center core and the coat is
an inner membrane that is similar to a regular cell
membrane. The spore also has an outer membrane
covering the coat that may correspond to the regular
bacterial cell wall peptidoglycan. Anthrax can infect
the host through intradermal inoculation, ingestion,
or inhalation of the spore. In vitro and in vivo stud-
ies have demonstrated that the dormant spores moni-
tor the environment until conditions are favorable for
growth. The spores then germinate and transform
through outgrowth (11 ). The germination process
consists of an irreversible series of degradative reac-
tions that result in the breaking of spore dormancy.
Although still poorly understood, it appears to be
essential for the development of the diseases caused
by anthrax. Once inhaled by animals or humans,
anthrax spores interact with alveolar macrophages,
which have been known to play a central role in in-
nate and acquired immune responses. They act as
guard cells to help clear invading bacteria from the
lung alveoli (5 , 6 ). Although understanding of cellu-
lar and molecular interactions between anthrax spores
and alveolar macrophages at the early stages of in-
fection is incomplete, it is known that the majority
of inhaled spores are rapidly and eﬃciently phagocy-
tosed by alveolar macrophages via recruitment of F-
actin (12 ). Germination of the anthrax spores occurs
once they have been phagocytosed by macrophages.
This is followed by extracellular multiplication, to-
gether with the production of a capsule and toxins
(including PA, LF, and EF). Thus the events occur-
ring at the early stage of anthrax infection, includ-
ing spore/macrophage interaction, germination, and
early outgrowth, may be promising immunologic and
pharmacologic targets against this organism. Arrest
of the anthrax life cycle at its onset would necessarily
preclude all downstream events including the lethal
manifestations of bacteremia and toxemia.
Proteomics to screen highly specific an-
thrax proteins
Currently, there are no anti-anthrax drugs that are
marketed for commercial use. The US anthrax vac-
cine that was licensed in 1970 is made from the ﬁl-
trate of a non-encapsulated attenuated strain (13 ).
This vaccine has unknown eﬃcacy, and often con-
tains impurities that can trigger local pain and edema
as well as other undesirable side eﬀects, such as
headaches and malaise (14 ). It has thus not been
readily accepted for public use. The emerging tech-
nology of proteomics may be useful in eliminating
antigen impurities. In addition, proteomics may also
help to detect unexpected changes in protein expres-
sion that may be missed by conventional biochemical
techniques (15 ). Speciﬁcally two-dimensional (2D)
electrophoresis gels can be used to separate thou-
sands of proteins quantitatively over a wide dynamic
range. Matrix-assisted laser-desorption-ionization-
time-of-ﬂight mass spectrometry (MALDI-TOF MS;
PerSeptive Biosystems Inc., Framingham, USA) and
quadrupole-time-of-ﬂight (Q-TOF) MS/MS (Micro-
mass, Manchester, UK) with high sensitivity have
been commonly used to identify and sequence spe-
ciﬁc proteins by generating peptides or even amino
acid mass “ﬁngerprints” of proteins, which are then
searched against a comprehensive computer database
(16 ). Identiﬁcation of spore proteins represents a cru-
cial step towards the development of anti-anthrax vac-
cines and drugs. Many anthrax proteins including
membrane proteins, spore coat proteins, and exospo-
rium glycoproteins have been identiﬁed via 2D elec-
trophoresis or a variety of mass spectrometric meth-
ods, including the multidimensional chromatography
tandem mass spectrometry and ion trap time-of-ﬂight
hybrid mass spectrometer (qIT-TOF MS; ref. 17–22).
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Fig. 1 The structure of dormant anthrax spore (Sterne strain). Spores were ﬁxed in modiﬁed Karnovsky’s ﬁxative
overnight at 4℃, which contained 2% paraformaldehyde, 2.5% glutaraldehyde, 0.06% CaCl2, in 0.1 M cacodylate buﬀer,
pH 7.4. Spores were then washed in 0.1 M cacodylate buﬀer, postﬁxed in 0.25% ruthenium tetroxide in 0.1 M cacodylate
for 45 min in the dark at the room temperature. The specimens were then rinsed in buﬀer, dehydrated in graded ethanol
solutions, and embedded in an Epon-epoxy resin mixture. Ultrathin 60–80 nm sections were examined under a Hitachi
7000 transmission electron microscope. Images were captured at 75 KV after staining with uranyl acetate/lead citrate.
E, exosporium; OC, outer coat membrane; C, coat; IC, inner coat membrane; CX, cortex. Bar, 0.2 µm. (Ref. 5 , 18 ,
and Huang, C.M., unpublished data).
To identify proteins involved in the early stage of
anthrax infection, we constructed 2D protein proﬁles
associated with anthrax germination and early out-
growth (11 ). By screening 587 paired protein spots
that were isolated from dormant and germinating
anthrax spores, respectively, we identiﬁed 10 spore
proteins with statistically signiﬁcant germination-
associated increases and decreases. In this review, we
will describe two proteases (immune inhibitor A and
GPR-like spore protease) and alanine racemase that
were diﬀerentially altered during the germination and
early outgrowth of anthrax spores. Based on infor-
mation in the literature and ﬁndings in our labora-
tory, we propose that these three proteins (immune in-
hibitor A, GPR-like spore protease, and alanine race-
mase) may play vital roles during the early stages
of anthrax infection. Developing vaccines and/or in-
hibitory drugs targeting these three proteins may be
an eﬀective strategy to prevent or halt the develop-
ment of the disease that this organism produces.
Immune Inhibitor A
Over 500 proteins from the dormant Sterne spore
strain were reproducibly displayed across an iso-
electric focusing (IEF) range of 4 to 7. A total of
50 protein spots (Figure 2A), corresponding to 36
diﬀerent anthrax proteins, were successfully identi-
ﬁed or sequenced by MALDI-TOF MS or Q-TOF 2
MS/MS (11 ). GeneMark predicted six hypothetical
proteins derived from the anthrax genome and these
were coded as unknown proteins. Following a pro-
tein sequence database search, one (spot 1) of the six
hypothetical proteins was shown to share 96% homol-
ogy with immune inhibitor A (gi|9858110) of Bacil-
lus thuringiensis (23 , 24 ). The level of immune in-
hibitor A was increased nearly two folds during ger-
mination and early outgrowth of anthrax (Figure 2).
To identify this protein spot, the spot was cut from
the silver-stained gels, in-gel digested with the trypsin
enzyme, and then analyzed on a PerSeptive Voyager-
DE MALDI-TOF MS. Peptide ﬁngerprint mass spec-
tra generated from MALDI-TOF MS were interpreted
and matched to SWISS-PROT database entries us-
ing Mascot (http://www.matrixscience.com). Sixteen
peaks within the peptide mass ﬁngerprint of spot 1
matched those of a protein with accession number
NP 843763 in the SWISS-PROT database (Figure 3).
The protein named as a hypothetical protein pre-
dicted by GeneMark is in fact a predicted protein
from the anthrax genome (25 ). By using a Q-TOF 2
MS/MS mass spectrometer, we have also determined
the internal sequence of this predicated protein at
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Fig. 2 Comparative proteomic proﬁles of dormant and germinating/early outgrowth anthrax (Sterne strain). Proteins
(300 µg) collected at 0 (A: dormant spores) and 10 min (B: germinating/early outgrowth anthrax) after incubation
were separated by 2D gels via pH 4–7 IEF and 12.5% SDS-PAGE (PolyAcrylamide Gel Electrophoresis), and then
silver-stained. Numbered protein spots indicated up- (circles) or down- (square) regulated expression compared to that
at time 0. Via MALDI-TOF MS and Q-TOF 2 MS/MS (8 ), spots 1, 2 and 3 have been identiﬁed as immune inhibitor
A, GPR-like spore protease, and alanine racemase, respectively.
Fig. 3 Proteomics identiﬁed immune inhibitor A of anthrax. Fingerprint mass spectra of MALDI-TOF MS (A) and
the predicted peptide fragments corresponding to observed m/z values (B) for spot 1 (Fig. 2) are shown (11 ). The
tryptic autodigestive peak at m/z value 2164.04 (asterisk) served as an internal calibration standard.
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amino acids between 450 and 463 with m/z value
at 1465.77 (Figure 4). All 14 amino acid residues
(GIGLATYLDQSVTK) from spot 1 were thus deter-
mined. More interestingly, the entire amino acid se-
quence of spot 1 of anthrax shares a high identity with
immune inhibitor A of Bacillus thuringiensis (Figure
4). Both of these proteins contain a HEXXH motif,
which is deﬁned as a zinc-binding domain of a metal-
loprotease (23 ), indicating that spot 1 may be a zinc-
dependent metalloprotease. Immune inhibitor A is a
secreted virulence protease from Bacillus thuringien-
sis and it speciﬁcally degrades two antibacterial pro-
teins (cecropins and attacins) produced by an insect
host (26 ), suggesting that it may contribute to the
overall virulence of Bacillus thuringiensis. Bacillus
thuringiensis is highly resistant to the insect immune
system due to its production of two factors, inhibitor
A and inhibitor B, which selectively block the hu-
moral defense system developed by insects against E.
coli and Bacillus cereus (24 ). Immune inhibitor A
is known to be a metalloprotease with similarity to
the thermolysin of Bacillus thermoproteolyticus, the
elastase of Pseudomonas aeruginosa, and the protease
E-15 from Serratia (23 ). It has been shown, using
the transcriptional immune inhibitor A’-lacZ fusion
construct, that expression of this protein occurs at
the onset of sporulation (27 ). Immune inhibitor A
has also been shown to be present as an active 73-
kDa polypeptide on the exosporium of Bacillus cereus
(28 ). These results demonstrate for the ﬁrst time that
immune inhibitor A is expressed in anthrax (Figures
2 and 3). Anthrax harbors the pXO1 plasmid, which
has been known to encode anthrax toxins including
PA/LF/EF. The pXO1 plasmid sequence of anthrax
is highly conserved among closely related bacterial
species including Bacillus thuringiensis (29 ), suggest-
ing that anthrax may possess many toxins, which are
highly similar to other bacillus species.
Fig. 4 Q-TOF 2 MS/MS peptide sequencing of immune inhibitor A (11 ). Designations for fragment ions from a
peptide (A). An internal peptide of immune inhibitor A with m/z value at 1465 analyzed by MALDI-TOF MS (Fig.
3) was sequenced by Q-TOF 2 MS/MS as GIGLATYLDQSVTK (B).
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GPR-like Spore Protease
The level of spot 2 was increased during spore germi-
nation and early outgrowth (Figure 2). Mass spec-
trometry matched this spot with protein accession
number NP 846769 in the SWISS-PROT database.
Since this protein shared 91% sequence identity with
the spore protease of Bacillus cereus and 67% identity
with the small, acid soluble proteins (SASP) degra-
dation spore germinate protease (GPR) precursor of
Bacillus subtilis (30 ), we assigned it GPR-like spore
protease. In the center of the dormant spore is the
spore core that contains most of the spore’s enzymes,
ribosomes and DNA (30 ). Enzymes that are present
in the dormant spore core are inactive, probably due
to very low water content in the core. It has been
shown that one of the mechanisms to protect the dor-
mant spore against external damaging eﬀects is sat-
uration of the spore chromosome with low molecular
weight proteins termed SASP (31 ). In the early stage
of spore germination, SASP are degraded by GPR.
Amino acids are then released for protein synthesis,
allowing DNA transcription and also releasing energy
for metabolism during the very early stages of ger-
mination and outgrowth. Studies in our laboratory
have demonstrated that the expression of GPR-like
spore protease is signiﬁcantly increased during germi-
nation and early outgrowth (Figure 2). The three-
dimensional structure and molecular mechanism of
GPR have recently been extensively investigated (10 ).
GPR-like spore protease could be an ideal target for
interventions to inﬂuence the early stage of anthrax
life cycle.
Alanine Racemase
Alanine racemase (spot 3, Figure 2) was found to
be strongly absorbed into the exosporium. Alanine
and inosine are the two major chemical triggers of
spore germination (32 ). Alanine racemase converts L-
ananine to D-alanine, a germination inhibitor and es-
sential component of the peptidoglycan found within
the cell wall and spore cortex (11 , 32 ). Its activity
is generally higher in spores than in vegetative cells
(11 , 33 ). The expression level of alanine racemase
was decreased during spore germination and early
outgrowth (11 , 32 ), supporting the hypothesis that
inhibition of this enzyme may be one of the prereq-
uisites for germination of anthrax spores. Expression
of alanine racemase in exosporium may allow inac-
tivation of this enzyme by speciﬁc antibodies or in-
hibitory drugs without the requirement of penetrating
a physical barrier. Inhibition of alanine racemase may
therefore minimize the survival potential of anthrax
by triggering premature germination of spores in a
suboptimal environment. It is thus possible to decon-
taminate an anthrax-spore-covered area by sprinkling
inhibitors targeting this enzyme in conjunction with
speciﬁc amino acids and nucleoside combinations that
trigger the gerA-like sensor operons (18 ) to induce
death of anthrax through pre-mature spore germina-
tion.
Challenges
An approach using 2D gels in conjunction with mass
spectrometry has been employed in an attempt to
look for candidate vaccines and/or drugs that specif-
ically target proteins expressed at the early stage of
anthrax infection. The amount of protein in a 2D gel
may be altered by numerous events including changes
in extractability from dormant and germinated/early-
outgrowth spores. Nonetheless, proteins character-
ized by 2D gels have a high probability of acting as
targets, given the magnitude of changes that are oc-
curring during germination. This makes it likely that
they play a critical role in germination, outgrowth,
maintenance, and stabilization of spores. Further
studies to determine the functions and distribution
of anthrax proteins that have been identiﬁed are es-
sential to the design of appropriate anti-anthrax vac-
cines and/or drugs. Immune inhibitor A has also been
shown to be present on the exosporium of Bacillus
cereus (28 ), but its location in Bacillus anthracis is
unknown. If immune inhibitor A is located within the
spores, antibodies or anti-anthrax drugs may be un-
able to gain access to this protein. The same challenge
is also present for GPR-like spore protease, which has
a high sequence homology with GPR, the protease ex-
pressed within the spore core of Bacillus cereus. Since
the spore core is protected by an inner membrane and
other physical layers outside of the core, it will be nec-
essary to design an intervention that can penetrate all
of these barriers to reach the spore core and react with
the GPR-like spore protease.
There are other challenges in the development
of vaccines/drugs targeting the early stages of an-
thrax infection. For example, once spores are inhaled,
portions of immune inhibitor A and alanine race-
mase may remain intracellular before macrophages
are lysed by anthrax toxins and/or immune inhibitor
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A. Alternatively, discharge of immune inhibitor A
and alanine racemase from dormant spores may oc-
cur within alveolar macrophages where they are be-
yond the reach of circulating antibodies or drugs. It
has been reported that multiple signal pathways may
be required for the breakdown of dormant anthrax
spores (34 ). Many molecules including immune in-
hibitor A, GPR-like spore protease, and alanine race-
mase may coordinate to trigger the early-outgrowth
of anthrax spores. Additionally, immune inhibitor A
may contribute to the cytotoxicity of anthrax spores
by working together with PA/LF/EF. If that is the
case, then multivalent vaccines or drugs that combine
PA/LF/EF and immune inhibitor A may be a novel
method of developing an eﬀective anti-anthrax rem-
edy.
Conclusion
The development of vaccines and/or inhibitory drugs
targeting speciﬁc proteins expressed during the early
stage of anthrax infection may be an eﬀective strategy
to halt the attack and spread of the disease (Figure
5). Blocking upstream processes (macrophage inter-
action, germination, and early outgrowth) that occur
early during an infection would prevent downstream
events including the production of its three natural
toxins, PA, LF and EF. The three anthrax proteins
(immune inhibitor A, GPR-like spore protease, and
alanine racemase) highlighted in this review have dif-
ferential expressions during spore germination and
outgrowth. Designing anti-anthrax vaccines and/or
drugs primarily targeting these three proteins rather
than PA, LF and EF may provide a safer and more
eﬀective approach to counteract anthrax.
Fig. 5 A cartoon showing the early stages of the anthrax life cycle. Three proteins (immune inhibitor A, •; GPR-like
spore protease, ; and alanine racemase, ) are thought to be involved in the spore germination/early outgrowth and
macrophage interaction. It has been reported that GPR-like spore protease and alanine racemase play an important
role in triggering the spore germination (11, 30, 33 ). Immune inhibitor A may be discharged from dormant spores
during the early stage of anthrax infection and facilitate anthrax invasion into host cells and escape the host immune
system. These proteins may be excellent potential targets for vaccines or inhibitory drugs.
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